TrialHuman vaccines & immunotherapeutics2021

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial.

Juliana Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.